Acute transverse myelitis revealing ankylosing spondylitis: A case report and literature review

Soumaya Boussaid1,2 | Safa Rahmouni1,2 | Sonia Rekik1,2 | Samia Jammali1,2 | Elhem Cheour2,3 | Hela Sahli1,2 | Mohamed Elleuch1,2

1Rheumatology Department, Rabta Hospital, Tunis, Tunisia
2Faculty of Medicine of Tunis, University Tunis el Manar, Tunis, Tunisia
3Pain Treatment Center, la Rabta hospital, Tunis, Tunisia

Correspondence
Soumaya Boussaid, Rheumatology Department, Rabta Hospital, Tunis, Tunisia.
Email: soumayaboussaid@hotmail.com

Abstract
When faced with a patient with acute myelopathy, thorough investigations should be undertaken to determine the cause. Ankylosing spondylitis should be kept in mind as a possible cause.

KEYWORDS
acute transverse myelitis, ankylosing spondylitis, spondyloarthritis

1 INTRODUCTION

Acute transverse myelitis is a rare condition affecting patients with long-standing spondyloarthritis (SpA). However, like in the present case, this condition may precede the SpA. Physicians may therefore pay attention and screen for SpA in patients presenting with acute transverse myelitis. Spondyloarthritis (SpA) is an umbrella term applied to a group of rheumatic diseases that share common pathophysiological, genetic, and clinical features, such as the involvement of the axial skeleton, peripheral manifestations (arthritis, enthesitis, and dactylytis), and extra-articular features. Radiographic axial spondyloarthritis, also known as ankylosing spondylitis (AS) is a specific subset of axial spondyloarthritis, characterized by radiographic structural changes in the sacroiliac joints. Systemic manifestations usually occur during the disease course. However, in rare cases, they can reveal the AS.

Nervous system involvement in AS is an uncommon extra-articular feature that often affects patients with long-standing disease. A wide range of neurological complications has been described including spinal cord or nerve compression as a result of atlantoaxial subluxation or vertebral fractures, cauda equina, monophasic myelopathy, and acute transverse myelitis (ATM).

ATM is a rare, acquired focal inflammatory spinal cord dysfunction seldom described in patients with long-standing AS. We report herein a case of ATM revealing AS in a previously healthy man.

1.1 Search strategy

We presented a case report along with the relevant literature regarding acute transverse myelitis in patients with AS. We performed a literature search in PubMed and Google Scholar using the terms: "Myelitis, Transverse" and "Spondylitis, Ankylosing" OR "Myelitis, Transverse" and "Arthritis, Psoriatic" OR "Myelitis, Transverse" and "Spondyloarthritis." The identified cases are shown in Table 1.
2 CASE REPORT

A 56-year-old man with a history of hypertension, visited our department for pain and numbness in the right lower limb (RLL). He did not report any family history of neurological disease. Over the past month, he developed progressive dysuria and erectile dysfunction. Clinical examination found muscular weakness of the RLL, increased lower extremity reflexes, T10 sensory level, and normal plantar reflex. The assessment of perineal sensation and anal tone did not reveal any abnormality. Sacral Thrust Test, Gaenslen test, Thrust, and Faber (or Patrick's) test were positive. The rest of the neuro-musculoskeletal examination was normal (in particular no peripheral joint involvement). Upon re-interviewing the patient, he reported inflammatory back pain for the past four months evolving since few months that was improved with non-steroidal anti-inflammatory drugs (NSAIDs).

Spinal cord magnetic resonance imaging (MRI) showed high signal intensity lesions of the central spine extending from T6 to T11 on T2-weighted images with enhancement after gadolinium. These findings were compatible with acute transverse myelitis (ATM). In addition, MRI showed Romanus lesions at the anterior vertebral corners of T7, T8, and T9, along with bone marrow edema of the sacroliac joints (Figure 1).

Thus, the diagnosis of AS was made based on the MRI findings according to the ASAS classification criteria for axial spondyloarthritis.

Laboratory examinations revealed high C-reactive protein levels (21.5mg/L), elevated erythrocyte sedimentation rate (56 mm/hour) with normal blood cell count. Serum electrolyte levels, liver, and renal function test results were normal.

We conducted several diagnostic studies in order to identify the cause of ATM. Serological testing did not indicate recent or active EBV, HSV I/II, human immunodeficiency virus, or hepatitis infection. Immunological tests including antinuclear antibodies and antineutrophil cytoplasmic antibodies were also negative. Cerebrospinal fluid (CSF) analysis showed normal cell count, protein, and glucose levels. CSF polymerase chain reactions (PCR) for Mycobacterium tuberculosis, Herpes simplex (HSV) I/II, cytomegalovirus, Epstein-Barr (EBV), and varicella-zoster viruses were negative. Therefore, we concluded that ATM was an AS extra-articular manifestation.

Our patient received intravenous methylprednisolone therapy (1000 mg for 3 consecutive days) with B vitaminotherapy. He was taught hygienic rules and had functional rehabilitation. Two weeks later, the patient was symptom-free. After 3 years of follow-up, his neurological status remained stable. As for the AS, he was treated with NSAIDs (Indomethacin, 150 mg/day) with good outcome.

3 DISCUSSION

Acute transverse myelitis (ATM) is a rare, acquired focal inflammatory spinal cord dysfunction. ATM typically presents with an acute to subacute onset weakness, sensory deficits, and bowel/bladder dysfunction without involvement of cranial nerve or cerebral function.

In a patient presenting with ATM, several etiologies should be considered. They can be broadly classified as para infectious process, paraneoplastic, drug or toxin-induced, systemic autoimmune disease, or acquired demyelinating disease. Several infectious agents have been suggested as potential causes of ATM including bacteria, viruses, fungi, and parasites.

Our patient had no history of infection and the workup did not show any signs of infection.

Like in any spinal cord disease, MRI represents an important diagnostic tool. ATM usually shows up as focal lesions of high signal intensity on the T2-weighted image (T2WI) with contrast enhancement in the spinal cord.

Acquired central nervous system autoimmune disorders including multiple sclerosis (MS), neumyelitis optica spectrum disorder, and acute disseminated encephalomyelitis also have been reported to be associated with ATM. However, clinical presentation, brain MRI, and CSF analysis did not support this diagnosis in our patient.

ATM can also be associated with systemic inflammatory autoimmune disorder. ATM in mixed connective tissue disease is not rare, notably systemic lupus erythematosus. It has been also described in Sjogren syndrome, antiphospholipid syndrome, 12 systemic sclerosis, 13 and mixed connective tissue disease. These disorders have been reported as possible causes of ATM.

In our patient, neither clinical signs and symptoms nor auto-antibody tests supported the diagnosis of systemic autoimmune disease. However, MRI showed signs suggestive of SpA (Figure 1).

In the present case, there was no clinical nor laboratory finding indicating any disease other than AS as the cause of ATM. Thus, we considered that ATM was an extra-articular feature of AS.

Nervous system involvement in SpA is an uncommon extra-articular complication often affecting patients with long-standing disease. In a large cohort of 1,472 Brazilian patients diagnosed with SpA, only 13 (0.9%) had neurological involvement, the most common of which were atlantoaxial subluxation and cauda equina syndrome. The association with multiple sclerosis (MS) has been previously reported too. In addition, patients with SpA are
| Author publication year | Gender | Age at diagnosis of ATM (year) | SpA subtype | Disease duration of SpA (year) | Clinical presentation of ATM | Imaging | Treatment | Outcome |
|--------------------------|--------|-------------------------------|-------------|-----------------------------|-----------------------------|--------|-----------|---------|
| Lan et al (2007)         | M      | 35                            | AS          | 15                          | Bilateral numbness along the upper limbs | NA     | Methylprednisolone pulse therapy | Complete remission. But 15 years later he developed ATM, acute arachnoiditis, and cauda equina syndrome |
| Oh et al (2001)          | M      | 26                            | AS          | 14                          | Rapid onset of motor weakness, tingling sensation in both legs, fecal incontinence. | Normal MRI | Methylprednisolone pulse therapy | Rapid improvement leading to complete clinical recovery after four weeks. |
| Rath et al (2010)        | F      | 50                            | PsA         | 8                           | 1-day history of rapidly ascending asymmetrical paresthesia, progressive painless weakness of the legs, urge incontinence. | A T2 hyperintense lesion of the central SC from T10 to the conus medullaris, without enhancement after gadolinium | Methylprednisolone pulse therapy | Good outcome |
| Sardana et al (2018)     | M      | NA                            | AS          | NA                          | Acute-onset quadriparesis with urinary retention | Long segment extensive spinal cord hyperintensity from C5-T1 to T3-T12 with minimal cord expansion in lower cervical and mid-lower thoracic SC | Methylprednisolone pulse therapy + long-term maintenance immunosuppressive therapy with Azathioprine |
| Hwang et al (2016)       | M      | 31                            | AS          | LBP for two years           | Claudication of the left lower extremity, sensory impairments | Diffuse swelling of the SC and signal changes (T6-7 to T8-9) | Methylprednisolone pulse therapy | Partial improvement |

Abbreviations: AS, ankylosing spondylitis; ATM, acute transverse myelitis; F, female; LBP, low back pain; M, male; NA, not available; PsA, psoriatic arthritis; SC, spinal cord; SpA, spondyloarthritis.
at higher risk of vertebral fractures. ATM, however, is exceptionally rare as there are only four clearly documented cases in AS patients and one case in a psoriatic arthritis (PsA) patient.

Even so, it is still unclear whether the association between ATM and AS is really underestimated or is just an accidental finding. The mechanism by which AS causes myelitis is not yet known. Several hypotheses have been suggested. The structural changes seen in the spinal canal during AS can be responsible for the bony impingement of spinal artery supplying the cord. However, in some cases, like in the present report, the MRI does not show any significant compression of the spinal cord. Besides, spinal cord inflammation due to AS could play a role in the pathophysiology of ATM. The good response to steroids and immunosuppressive agents supports this hypothesis.

The association of multiple sclerosis and AS is more common and has received greater attention. Although the etiology of this association has not been fully elucidated, several hypotheses have been proposed.

Genetic and environmental factors play a major role in the occurrence of both diseases.

In fact, AS and MS share a genetic predisposition. It has been reported that the HLA-B7 haplotype is commonly seen in both diseases. A possible HLA cross-reactivity between AS and MS, especially for HLA-B27, has also been evoked.

Of note, the frequency of HLA-B27 ranges from 88 to 90% in AS patients and is about 10% in MS patients controls and 8% of the general population worldwide.

Regarding the characteristics of AS patients with ATM, all patients but one were male.

However, unlike our patient, ATM occurred later in the course of disease. To the best of our knowledge, this is the first case of ATM revealing AS.

In the majority of reported cases, the diagnosis of AS preceded the initial symptoms of ATM from eight to 15 years. This suggests that ATM is rather a complication of long-standing AS. However, Hwang et al. described a patient who had experienced back pain for two years prior to the onset of ATM symptoms, but the diagnosis of AS was made at the same time as the ATM.

In the present case, the patient had experienced inflammatory low back pain during the past four months. The diagnosis of AS was made based on the findings spotted on MRI.

Although ATM, as the first manifestation of AS, is an unusual presentation, it should be considered in AS patients with neurological symptoms.

The first-line therapy for ATM is intravenous glucocorticoids pulses. Immunosuppressive agents such as cyclophosphamide, mycophenolate, or rituximab may be efficacious in chronic recurrent TM or resistant acute TM. Patients with acute central nervous system demyelinating disease who failed to respond to glucocorticoid therapy can benefit from plasma exchange. Like all the reported cases, our patient responded well to intravenous glucocorticoids pulses.

TNF-inhibitors drugs (TNFi) are new therapeutic agents that have revolutionized the management of spondyloarthritis. Although generally well tolerated, numerous studies have raised the possibility that TNFi may be responsible for central or peripheral nervous system demyelinating disorders. The co-existence of AS and ATM has large impact on the treatment strategy since there have been few reports of patients with AS who developed ATM while being treated with TNFi.

Patients with AS or PsA treated with TNFi have 50% increased risk of a neuroinflammatory disease compared with those who are not. The mechanism of demyelination associated with TNFi is yet to be determined.
Since TNF-alpha modulates the autoreactive T cells reactivity to self-antigens, its inhibition can result in an increased activity of autoreactive T cells. This phenomenon was suggested to be responsible for the autoimmune damage of the myelin sheaths.31

Given that TNFalpha can cause a decrease in immune response, the discontinuation of the treatment can result in immune reconstitution syndrome causing the autoimmune demyelination.

Thus, it seems reasonable to consider an alternative therapy other than TNFi in patients with a personal or family history of demyelinating disease.

In conclusion, when faced with a patient with an acute myelopathy, a thorough investigation should be undertaken to determine the cause. AS should be kept in mind as a possible cause of ATM and should be treated as soon as possible since it is a potential handicapping condition.

To the best of our knowledge, this is the first case report of ATM revealing an AS. In-depth studies of the pathophysiologies of these two conditions are needed to better elucidate the link between them.

CONFLICTS OF INTEREST
We declare that we have no conflict of interest.

AUTHOR CONTRIBUTIONS
Dr Soumaya Boussaid: Conceptualization, Writing—original draft, Supervision, Revision, and Validation. Dr Safa Rahmouni: Data curation, Writing—original draft, and Revision. Dr Sonia Rekik, Dr Elhem Cheour, Dr Sahli Hela, and Dr Mohamed Elleuch: Supervision and Validation. Dr Samia Jemmali: Writing—original draft.

ETHICAL APPROVAL
This study was approved by the ethical committee of la Rabta Hospital.

CONSENT
We have obtained the patient’s consent for publication before inclusion in this study.

DATA AVAILABILITY STATEMENT
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

ORCID
Soumaya Boussaid https://orcid.org/0000-0002-9185-1710
Safa Rahmouni https://orcid.org/0000-0001-7955-8653

REFERENCES
1. Mercieca C, van der Horst-Bruinsma IE, Borg AA. Pulmonary, renal and neurological comorbidities in patients with ankylosing spondylitis; implications for clinical practice. Curr Rheumatol Rep. 2014;16(8):434.
2. Stolwijk C, Essers I, van Tubergen A, et al. The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study. Ann Rheum Dis. 2015;74(7):1373-1378.
3. Fox MW, Onofrio BM, Kilgore JE. Neurological complications of ankylosing spondylitis. J Neurosurg. 1993;78(6):871-878.
4. Oh DH, Jun JB, Kim HT, et al. Transverse myelitis in a patient with long-standing ankylosing spondylitis. Clin Exp Rheumatol. 2001;19(2):195-196.
5. Simone CG, Emmady PD. Transverse Myelitis. In: StatPearls [Internet]. StatPearls Publishing; 2021 [cited 31 mars 2021]. Disponible sur: http://www.ncbi.nlm.nih.gov/books/NBK559302/
6. Beh SC, Greenberg BM, Frohman T, Frohman EM. Transverse myelitis. Neurol Clin. 2013;31(1):79-138.
7. Goh C, Desmond PM, Phal PM. MRI in transverse myelitis. J Magn Reson Imaging. 2014;40(6):1267-1279.
8. Gastaldi M, Marchioni E, Banfi P, et al. Predictors of outcome in a large retrospective cohort of patients with transverse myelitis. Mult Scler. 2018;24(13):1743-1752.
9. Bhat A, Naguwa S, Cheema G, Gershwin ME. The epidemiology of transverse myelitis. Autoimmun Rev. 2010;9(5):A395-A399.
10. Hryb JP, Chiganer E, Contentti EC, Di Pace JL, Lessa C, Perassolo MB. Myelitis in systemic lupus erythematosus: clinical features, immunological profile and magnetic resonance imaging of five cases. Spinal Cord Ser Cases. 2016;2:16005.
11. Menor Almagro R, Ruiz Tudela MDM, Girón Úbeda J, Cardiel Rios MH, Pérez Venegas JJ, García Guijo C. Myelitis transverse in Sjögren’s syndrome and systemic lupus erythematosus: presentation of 3 cases. Reumatol Clin. 2015;11(1):41-44.
12. Kim JH, Lee SI, Park SI, Yoo WH. Recurrent transverse myelitis in primary antiphospholipid syndrome–case report and literature review. Rheumatol Int. 2004;24(4):244-246.
13. Torabi AM, Patel RK, Wolfe GI, Hughes CS, Mendelsohn DB, Trivedi JR. Transverse myelitis in systemic sclerosis. Arch Neurol. 2004;61(1):126.
14. Mok CC, Lau CS. Transverse myelopathy complicating mixed connective tissue disease. Clin Neurol Neurosurg. 1995;97(3):259-260.
15. Rodrigues CEM, Vieira WP, Bortoluzzo AB, et al. Low prevalence of renal, cardiac, pulmonary, and neurological extra-articular clinical manifestations in spondyloarthritis: analysis of the Brazilian Registry of Spondyloarthritis. Revista Brasileira de Reumatologia. 2012;52(3):379-383.
16. Hanrahan PS, Russell AS, McLean DR. Ankylosing spondylitis and multiple sclerosis: an apparent association? J Rheumatol. 1988;15(10):1512-1514.
17. Fominykh V, Shevtsova T, Arzumanian N, Brylev L. Coexistence of multiple sclerosis and ankylosing spondylitis: report of four cases from Russia and review of the literature. J Clin Neurosci. 2017;44:230-233.
18. Lan HH-C, Chen D-Y, Chen CC-C, Lan J-L, Hsieh C-W. Combination of transverse myelitis and arachnoiditis in cauda
equina syndrome of long-standing ankylosing spondylitis: MRI features and its role in clinical management. Clin Rheumatol. 2007;26(11):1963-1967.

19. Rath JIG, Ronday HK, Wirtz PW. Acute transverse myelitis in psoriatic arthritis. J Neurol. 2010;257(3):457-458.

20. Sardana V, Sharma S, Maheshwari D, Bhushan B. Long segment extensive transverse myelitis in a patient of ankylosing spondylitis. Ind J Rheumatol. 2018;13(2):133.

21. Jersild C, Svejgaard A, Fog T. HLA-A antigens and multiple sclerosis. Lancet. 1972;1(7762):1240-1241.

22. Parasannanavar DJ, Rajadhyaksha A, Ghosh K. Role of hla-B alleles and clinical presentation of b27 negative spondyloarthrits patients from Mumbai, Western India. Autoimmune Dis. 2014;2014:327315.

23. Libbrecht N, De Bleecker J. Ankylosing spondylitis and multiple sclerosis. Acta Clin Belg. 1999;54(1):30-32.

24. Nazarinia MA, Ghaffarpasand F, Heiran HR, Habibagahi Z. Pattern of ankylosing spondylitis in an Iranian population of 98 patients. Mod Rheumatol. 2009;19(3):309-315.

25. Reveille JD. HLA-B27 and the seronegative spondyloarthropathies. Am J Med Sci. 1998;316(4):239-249.

26. Hwang DW, Kim JH, Kim JJ, et al. Ankylosing spondylitis associated with acute transverse myelitis. Korean J Med. 2016;80(Suppl 2):S314-S318.

27. Kemanetzoglou E, Andreadou E. CNS demyelination with TNF-α Blockers. Curr Neurol Neurosci Rep. 2017;17(4).

Disponible sur: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5364240/

28. Escalas J, Knöpfel N, Martin-Santiago A, Calles C. Acute transverse myelitis during treatment with etanercept for severe plaque psoriasis. J Am Acad Dermatol. 2014;70(1):e17-e18.

29. Cay HF, Gungor HA, Sezer I, Kacar C, Balcı N. Adverse effect of TNF-alpha blocker? Demyelination in an ankylosing spondylitis patient: a case report. J Clin Pharm Ther. 2006;31(6):645-648.

30. Kopp TI, Delcoigne B, Arkema EV, et al. Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden. Ann Rheum Dis. 2020;79(5):566-572.

31. Kucharz EJ, Kotulska-Kucharz A. Tumor necrosis factor alpha inhibitors and demyelinating disease: what is behind it? Reumatologia. 2021;59(2):65-67.

How to cite this article: Boussaid S, Rahmouni S, Rekik S, et al. Acute transverse myelitis revealing ankylosing spondylitis: A case report and literature review. Clin Case Rep. 2021;9:e04878. https://doi.org/10.1002/ccr3.4878